Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 9/20 | 0.69 |
| ▸ | CTSL | P07711 | 3/20 | 0.64 |
| ▸ | CTSS | P25774 | 3/20 | 0.64 |
| ▸ | CTSK | P43235 | 3/20 | 0.64 |
| ▸ | CTSH | P09668 | 1/20 | 0.64 |
| ▸ | CCKBR | P32239 | 6/20 | 0.63 |
| ▸ | MC4R | P32245 | 1/20 | 0.61 |
| ▸ | MC5R | P33032 | 1/20 | 0.61 |
| ▸ | MC3R | P41968 | 1/20 | 0.61 |
| ▸ | MC1R | Q01726 | 1/20 | 0.61 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23928719 | 0.87 | CCKBR (0.67) | CXCL8CCKBR | |
| SCHEMBL29349773 | 0.87 | CCKBR (0.67) | CXCL8CCKBR | |
| SCHEMBL29362913 | 0.87 | CCKBR (0.67) | CXCL8CCKBR | |
| SCHEMBL11778234 | 0.85 | PTGS1 (0.67) | CXCL8MC4RMC5RMC3RMC1R | |
| SCHEMBL31694508 | 0.85 | CXCR4 (0.66) | CXCR4 | |
| SCHEMBL29389654 | 0.84 | MC4R (0.67) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL29150398 | 0.84 | CCKBR (0.62) | CXCL8CCKBR | |
| SCHEMBL11589771 | 0.84 | GNRHR (0.63) | CXCL8CXCR4 | |
| SCHEMBL30527868 | 0.84 | GLP1R (0.71) | CXCL8 | |
| SCHEMBL11589351 | 0.83 | GNRHR (0.68) | CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122081231-A | Culture medium and culture method for small intestine tumor organoids | — | 2026-05-26 | — | — | CN | claimed |
| US-20250283048-A1 | PLATELET-ACTIVATING FACTOR BLOCKADE INHIBITS TUMOR GROWTH | THE JOHNS HOPKINS UNIVERSITY | 2025-09-11 | — | — | US | claimed |
| CN-120158421-A | Co-differentiated vascularized liver organoid and construction method thereof | 四川大学 | 2025-06-17 | — | — | CN | claimed |
| US-20250171542-A1 | ANTI-PROGRAMMED DEATH-LIGAND 1 (PD-L1) ANTIBODIES | ADEPT BIOPHARMACEUTICAL AND TECHNOLOGY LTD. (CN) | 2025-05-29 | — | — | US | claimed |
| CN-119410587-B | Rectal tumor organoid chip drug sensitivity detection kit and application method thereof | 黑玉星岩国际科学技术(北京)有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119799640-A | Method for culturing pancreatic cancer and paracancerous organoids | 重庆市人民医院 | 2025-04-11 | — | — | CN | claimed |
| CN-119709621-A | Hepatocellular carcinoma organoid-T cell co-culture system, construction method and application thereof | 中国人民解放军海军军医大学第三附属医院 | 2025-03-28 | — | — | CN | claimed |
| CN-119410587-A | Rectal tumor organoid chip drug sensitivity detection kit and application method thereof | 黑玉星岩国际科学技术(北京)有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-119331974-A | Mucinous pancreatic cystic tumor organoid culture method, detection method and system | 上海万何圆生物科技有限公司 | 2025-01-21 | — | — | CN | claimed |
| EP-4486783-A2 | ANTI-PROGRAMMED DEATH-LIGAND 1 (PD-L1) ANTIBODIES | Adept Therapeutics Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| CN-114717182-A | Molecular culture medium for 3D culture of goat colon organoid | 中国科学院亚热带农业生态研究所 | 2022-07-08 | — | — | CN | claimed |
| CN-114561340-A | Culture medium for culturing recurrent breast cancer organoid and application thereof | 上海诺典生物科技有限公司 | 2022-05-31 | — | — | CN | claimed |
| CN-114480287-A | Recurrent lung cancer puncture sample organoid culture medium and application thereof | 宋伟 | 2022-05-13 | — | — | CN | claimed |
| CN-114480288-A | Culture medium for culturing enterosignet ring cell carcinoma organoid | 上海诺典生物科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-114181886-A | Application of three-dimensional culture system in intestinal epithelial organoids of Bama pigs and cynomolgus monkeys | 清华大学 | 2022-03-15 | — | — | CN | claimed |
| CN-114181903-A | Colorectal cancer organoid culture medium and stent-free 3D culture method | 浙江弘瑞医疗科技有限公司 | 2022-03-15 | — | — | CN | claimed |
| CN-112210537-B | Liver cancer organoid and culture method, culture medium for culture and application thereof | 北京科途医学科技有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-108148811-B | Method for establishing xenograft tumor model derived from colorectal cancer patient based on temperature-sensitive biological gel three-dimensional culture system | 复旦大学附属中山医院 | 2022-03-01 | — | — | CN | claimed |
| EP-3512935-B1 | METHODS RELATING TO INTESTINAL ORGAN-ON-A-CHIP | HARVARD COLLEGE (US) | 2022-02-23 | — | — | EP | claimed |
| CN-114032277-A | Method for detecting drug sensitivity of tumor organoid based on staining method | 创芯国际生物科技(广州)有限公司 | 2022-02-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250283048-A1 | PLATELET-ACTIVATING FACTOR BLOCKADE INHIBITS TUMOR GROWTH | PTAFR, PTGFR, PTGIR | CXCL8 520/4885CTSL 3916/4885CTSS 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.